Reviewer’s report

Title: Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-up

Version: 0 Date: 29 Mar 2020

Reviewer: Sunil Agrawal

Reviewer's report:

It is a good article but in my view needs certain clarifications:

1. In the "Intervention" heading it is mentioned as double blind study and study material was prepared by the hospital pharmacy. It is mentioned that in Group U the whole medicine was transfused after induction and only normal saline was infused after giving protamine. If they were blind about the medicine then how come they changed the protocol in Group U.

2. Blood loss in first 24 hour is more significant as after that mostly it is serous loss.

3. Looking into the group Trenexamic group had better results.

4. Cost effectiveness of Ulinastatin vs Trenexamic acid was not discussed.

5. More than 15% patients were lost in follow-up which is a significant number looking into small sample size.

Level of interest
Please indicate how interesting you found the manuscript:

An article whose findings are important to those with closely related research interests

Quality of written English
Please indicate the quality of language in the manuscript:

Not suitable for publication unless extensively edited

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests'

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.